Literature DB >> 18334133

Diagnosis and treatment of multifocal motor neuropathy.

Ryuji Kaji1.   

Abstract

Multifocal motor neuropathy (MMN) is a unique disease mimicking motor neuron disease, but it is treatable with intravenous immunoglobulins. Anti-GM1 IgM antibody titers are not sensitive enough to predict the outcome. Electrodiagnosis is essential for the diagnosis of MMN. Conduction block has been suggested as the best diagnostic marker, but it is not found in all treatable cases. Activity-dependent conduction changes, as revealed by comparing conduction before and after maximal voluntary contraction of the muscle, are a convenient and promising tool. Treatment options include various immunosuppressants (including cyclophosphamide), but there has not been ample evidence in favor of any of these agents in randomized controlled trials. Intravenous immunoglobulins remain the mainstay for treating MMN.

Entities:  

Year:  2008        PMID: 18334133     DOI: 10.1007/s11940-008-0012-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  20 in total

1.  Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block.

Authors:  Matthew C Kiernan; Jean-Marc Guglielmi; Ryuji Kaji; Nicholas M F Murray; Hugh Bostock
Journal:  Brain       Date:  2002-03       Impact factor: 13.501

2.  High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy.

Authors:  Thomas H Brannagan; Armin Alaedini; Douglas E Gladstone
Journal:  Muscle Nerve       Date:  2006-08       Impact factor: 3.217

3.  Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study.

Authors:  J P Azulay; O Blin; J Pouget; J Boucraut; F Billé-Turc; G Carles; G Serratrice
Journal:  Neurology       Date:  1994-03       Impact factor: 9.910

4.  [The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy].

Authors:  T Kubori; T Mezaki; R Kaji; J Kimura; K Hamaguchi; K Hirayama; I Kanazawa; T Miyatake; T Mannen; H Kowa; N Yanagisawa; I Goto; M Osame; M Kanda; K Tashiro; M Baba; Y Kuroiwa; H Nagatomo; T Mitsuma; Y Shigeta; T Saida; K Nakajima; J Kawamura; Y Murai; T Kiuchi
Journal:  No To Shinkei       Date:  1999-02

5.  Mycophenolate in treatment-resistant inflammatory neuropathies.

Authors:  T Umapathi; R Hughes
Journal:  Eur J Neurol       Date:  2002-11       Impact factor: 6.089

6.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.

Authors:  A Pestronk; D R Cornblath; A A Ilyas; H Baba; R H Quarles; J W Griffin; K Alderson; R N Adams
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

7.  Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test.

Authors:  H Nodera; H Bostock; Y Izumi; K Nakamura; R Urushihara; T Sakamoto; N Murase; H Shimazu; S Kusunoki; R Kaji
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

8.  Multifocal motor neuropathy: the diagnostic spectrum and response to treatment.

Authors:  Mark Slee; Arul Selvan; Michael Donaghy
Journal:  Neurology       Date:  2007-10-23       Impact factor: 9.910

9.  Pathological findings at the site of conduction block in multifocal motor neuropathy.

Authors:  R Kaji; N Oka; T Tsuji; T Mezaki; T Nishio; I Akiguchi; J Kimura
Journal:  Ann Neurol       Date:  1993-02       Impact factor: 10.422

10.  Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.

Authors:  Sanne Piepers; Renske Van den Berg-Vos; W-Ludo Van der Pol; Hessel Franssen; John Wokke; Leonard Van den Berg
Journal:  Brain       Date:  2007-07-10       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.